PRA Health Sciences (PRAH) Lowered to Strong Sell at BidaskClub

Share on StockTwits

BidaskClub cut shares of PRA Health Sciences (NASDAQ:PRAH) from a sell rating to a strong sell rating in a report published on Wednesday, BidAskClub reports.

Several other brokerages also recently weighed in on PRAH. Robert W. Baird raised their price target on shares of PRA Health Sciences from $119.00 to $122.00 and gave the company an outperform rating in a research report on Thursday, February 28th. Wolfe Research assumed coverage on shares of PRA Health Sciences in a research report on Tuesday, April 2nd. They set a market perform rating for the company. SunTrust Banks raised their price target on shares of PRA Health Sciences to $120.00 and gave the company an average rating in a research report on Monday, March 4th. ValuEngine raised shares of PRA Health Sciences from a hold rating to a buy rating in a research report on Monday, February 4th. Finally, Mizuho set a $100.00 price target on shares of PRA Health Sciences and gave the company a hold rating in a research report on Friday, May 3rd. One analyst has rated the stock with a sell rating, six have issued a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus price target of $113.22.

Shares of PRAH opened at $89.05 on Wednesday. The company has a market cap of $5.85 billion, a P/E ratio of 22.66, a PEG ratio of 1.16 and a beta of 1.01. The company has a quick ratio of 0.90, a current ratio of 0.90 and a debt-to-equity ratio of 0.97. PRA Health Sciences has a twelve month low of $80.28 and a twelve month high of $121.98.

PRA Health Sciences (NASDAQ:PRAH) last announced its quarterly earnings results on Wednesday, February 27th. The medical research company reported $1.21 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.18 by $0.03. The company had revenue of $729.65 million during the quarter, compared to the consensus estimate of $750.67 million. PRA Health Sciences had a net margin of 5.50% and a return on equity of 26.87%. On average, sell-side analysts anticipate that PRA Health Sciences will post 4.63 EPS for the current fiscal year.

Hedge funds have recently modified their holdings of the stock. Cresset Asset Management LLC purchased a new stake in PRA Health Sciences in the first quarter worth approximately $25,000. Motco boosted its holdings in PRA Health Sciences by 937.0% in the first quarter. Motco now owns 280 shares of the medical research company’s stock worth $31,000 after purchasing an additional 253 shares during the last quarter. Rockefeller Capital Management L.P. purchased a new stake in PRA Health Sciences in the first quarter worth approximately $37,000. Financial Gravity Wealth Inc. purchased a new stake in PRA Health Sciences in the first quarter worth approximately $53,000. Finally, Manchester Capital Management LLC purchased a new stake in PRA Health Sciences in the first quarter worth approximately $57,000. Institutional investors own 99.09% of the company’s stock.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Read More: What is the Fibonacci sequence?

Analyst Recommendations for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Slack  Earns Neutral Rating from Analysts at Credit Suisse Group
Slack Earns Neutral Rating from Analysts at Credit Suisse Group
Slack  Coverage Initiated by Analysts at Morgan Stanley
Slack Coverage Initiated by Analysts at Morgan Stanley
Solaris Oilfield Infrastructure  Coverage Initiated by Analysts at Citigroup
Solaris Oilfield Infrastructure Coverage Initiated by Analysts at Citigroup
Tanger Factory Outlet Centers  Upgraded to “Hold” at Zacks Investment Research
Tanger Factory Outlet Centers Upgraded to “Hold” at Zacks Investment Research
Sterling Bancorp  Coverage Initiated at B. Riley
Sterling Bancorp Coverage Initiated at B. Riley
Restoration Hardware  Upgraded by ValuEngine to “Hold”
Restoration Hardware Upgraded by ValuEngine to “Hold”


© 2006-2019 Ticker Report